- Home
- CCIX vs MBX Comparison
CCIX vs MBX Comparison
Compare CCIX & MBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCIX
- MBX
- Stock Information
- Founded
- CCIX 2023
- MBX 2018
- Country
- CCIX United States
- MBX United States
- Employees
- CCIX N/A
- MBX N/A
- Industry
- CCIX
- MBX
- Sector
- CCIX
- MBX
- Exchange
- CCIX Nasdaq
- MBX NYSE
- Market Cap
- CCIX 394.1M
- MBX 347.9M
- IPO Year
- CCIX 2024
- MBX 2024
- Fundamental
- Price
- CCIX $10.75
- MBX $7.38
- Analyst Decision
- CCIX
- MBX Strong Buy
- Analyst Count
- CCIX 0
- MBX 4
- Target Price
- CCIX N/A
- MBX $37.25
- AVG Volume (30 Days)
- CCIX 22.0K
- MBX 218.2K
- Earning Date
- CCIX 01-01-0001
- MBX 03-17-2025
- Dividend Yield
- CCIX N/A
- MBX N/A
- EPS Growth
- CCIX N/A
- MBX N/A
- EPS
- CCIX N/A
- MBX N/A
- Revenue
- CCIX N/A
- MBX N/A
- Revenue This Year
- CCIX N/A
- MBX N/A
- Revenue Next Year
- CCIX N/A
- MBX N/A
- P/E Ratio
- CCIX N/A
- MBX N/A
- Revenue Growth
- CCIX N/A
- MBX N/A
- 52 Week Low
- CCIX $10.00
- MBX $7.16
- 52 Week High
- CCIX $11.17
- MBX $27.50
- Technical
- Relative Strength Index (RSI)
- CCIX N/A
- MBX N/A
- Support Level
- CCIX N/A
- MBX N/A
- Resistance Level
- CCIX N/A
- MBX N/A
- Average True Range (ATR)
- CCIX 0.00
- MBX 0.00
- MACD
- CCIX 0.00
- MBX 0.00
- Stochastic Oscillator
- CCIX 0.00
- MBX 0.00
About CCIX Churchill Capital Corp IX Ordinary Shares
Churchill Capital Corp IX is a blank check company.
About MBX MBX BIOSCIENCES INC
MBX Biosciences Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include MBX 2109, MBX 1416, and MBX 4291.